Implantable Nanofluidic Device Delivers CD40 Antibody & Shrinks Pancreatic Tumors in Animal Model

Houston Methodist nanomedicine researchers have found a way to possibly tame pancreatic cancer--one of the most aggressive and difficult to treat cancers--by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice. In a paper published on January 13, 2023 in Advanced Science, Houston Methodist Research Institute researchers described using an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAbs), a promising immunotherapeutic agent, at a sustained low-dose via the nanofluidic drug-eluting seed (NDES). The result, found in murine models, was tumor reduction at a four-fold lower dosage than traditional systemic immunotherapy treatment. The article is titled “Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.”
Login Or Register To Read Full Story